Related Experiment Video
Updated: Apr 11, 2026
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments
Anurag Saxena1, Julian R Sampson1
1Division of Cancer and Genetics, Cardiff University School of Medicine, Institute of Medical Genetics, Cardiff, United Kingdom.
Insights
Epilepsy is common in tuberous sclerosis, often starting in childhood. New mTORC1 inhibitors show promise as novel antiepileptic drugs for this genetic disorder.
Area of Science:
- Neurology
- Genetics
- Pharmacology
Background:
- Tuberous sclerosis is a genetic disorder affecting multiple systems.
- Epilepsy affects 75-90% of individuals with tuberous sclerosis, typically with onset in infancy or childhood.
- Current antiepileptic drug treatments are often unsatisfactory, leading to polypharmacy.
Purpose of the Study:
- To review the role of mammalian target of rapamycin complex 1 (mTORC1) signaling in tuberous sclerosis-associated epilepsy.
- To discuss the potential of mTORC1 inhibitors as novel antiepileptic treatments.
Main Methods:
- Review of existing literature on tuberous sclerosis, epilepsy, and mTORC1 signaling.
- Analysis of recent studies on mTORC1 inhibitors in tuberous sclerosis manifestations.
- Assessment of mTORC1 inhibitors as potential antiepileptic drugs.
Main Results:
- Mutations in TSC1/TSC2 genes cause tuberous sclerosis and lead to mTORC1 hyperactivation.
- mTORC1 inhibitors have demonstrated efficacy in treating some tuberous sclerosis symptoms.
- Ongoing research is evaluating mTORC1 inhibitors for epilepsy in tuberous sclerosis.
Conclusions:
- mTORC1 signaling is a key pathway in tuberous sclerosis pathogenesis.
- mTORC1 inhibitors represent a promising therapeutic strategy for epilepsy in tuberous sclerosis.
- Further investigation is warranted to establish the role of mTORC1 inhibitors in managing tuberous sclerosis-associated epilepsy.
Abstract:
Epilepsy affects 75% to 90% of people with tuberous sclerosis, a multisystem genetic disorder. Although seizures can occur for the first time at any age, onset in infancy or childhood is usual. Around 30% of patients present with infantile spasms that often respond well to treatment with vigabatrin. Later seizures may occur as specific patterns, such as in Lennox-Gastaut syndrome, or with combinations of seizures including focal and multifocal seizures, and drop attacks. Most patients have two or more seizure types. Seizure control using current antiepileptic drugs is often unsatisfactory, leading to frequent polypharmacy. Epilepsy surgery has a place in the management of some patients. Mutations in the TSC1 and TSC2 genes that cause tuberous sclerosis lead to hyperactivation of signaling via the mammalian target of rapamycin complex 1 (mTORC1). Inhibitors of mTORC1 have recently been shown to be effective treatments for some manifestations of tuberous sclerosis; they are now being assessed as potential novel antiepileptic drugs in tuberous sclerosis and related disorders.
More Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:13Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...